Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
A growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy.
-
Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment.
-
Alzheimer's disease (AD) is a main cause of dementia, accounting for up to 75% of all dementia cases.
-
Cholinergic synapses are ubiquitous in the human central nervous system.
-
Neurodegenerative diseases are increasing in number, given that the general global population is becoming older.
-
41/100
In mammals, a central circadian clock, located in the suprachiasmatic nuclei (SCN) of the hypothalamus, tunes the innate circadian physiological rhythms to the ambient 24 h light-dark cycle to invigorate and optimize the internal temporal order.
-
41/100
Overall, ARIA-E was mild and asymptomatic.
-
There are currently 24 agents in 36 trials in phase III of AD drug development.
-
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD).
-
The risk of dementia increases steadily with the number of medications used and age in older people in Taiwan.
-
The past 30 years have seen multiple attempts at demonstrating the safety and efficacy of drugs for Alzheimer's disease (AD), predominantly to improve symptoms.
-
This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.
-
In 2004, estimated prevalence of ChI use among subjects with dementia ranged from 3.0% in the Netherlands to 20.3% in France.
-
These data suggest that AH medications, and specifically potassium-sparing diuretics, are associated with reduced incidence of AD.
-
All cholinesterase inhibitors reduced cognitive deficits with the following optimal daily doses: galantamine 1.25 mg kg(-1), rivastigmine 0.5 mg kg(-1) and donepezil 0.3 mg kg(-1).
-
The neurotransmitter acetylcholine is considered essential for proper functioning of the hippocampus-dependent declarative memory system, and it represents a major neuropharmacological target for the treatment of memory deficits, such as those in Alzheimer's disease.
-
Alzheimer’s disease (AD) is caused by the build-up of amyloid beta (A$\beta$) proteins in the brain, leading to memory loss and cognitive decline.
-
Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab.
-
Alzheimer's disease (AD) is a major global public health challenge.
-
Epidemiological evidence has revealed a link between AD/PD and type 2 diabetes mellitus, with these disorders sharing some pathological commonalities.
-
40/100
Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide.
-
Based on the data to date, it is difficult to accurately assess the role of aducanumab in patients with MCI or mild AD.
-
Despite presence of substantial evidence suggesting the pivotal role of amyloid (Aβ) in Alzheimer's disease (AD), very few therapeutic agents have been able to ameliorate the disease.
-
40/100
Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid β.
-
The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaicin results in compounds with nanomolar potencies toward human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) that retain or improve the antioxidant properties of capsaicin.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Treatment of Alzheimer's disease: current status and new perspectives
- Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier
- Representation of patients with dementia in clinical trials of donepezil
- Avoiding Over-Reliance on Multi-Domain Interventions for Dementia Prevention
- Budget Impact Analysis of Disease-Modifying Therapies for Alzheimer’s Disease in Ireland: A Model-Based Analysis
- The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches
- [Toward a preventive management Alzheimer's disease]
- Physical exercise protocols in animal models of Alzheimer's disease: a systematic review
- An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease
- Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis